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CD200 induces immunosuppression inmyeloid cells expressing its receptor CD200R,whichmay have consequences
for tumor immunity. We found that human carcinoma tissues express not only full-length CD200 (CD200L) but also its
truncated form, CD200S. Although CD200S is reported to antagonize the immunosuppressive actions of CD200L, the
role of CD200S in tumor immunity has never been investigated.We established rat C6 glioma cell lines that expressed
either CD200L or CD200S; the original C6 cell line did not express CD200 molecules. The cell lines showed no
significant differences in growth. Upon transplantation into the neonatal Wistar rat forebrain parenchyma, rats
transplanted with C6-CD200S cells survived for a significantly longer period than those transplanted with the original
C6 and C6-CD200L cells. The C6-CD200S tumors were smaller than the C6-CD200L or C6-original tumors, and many
apoptotic cells were found in the tumor cell aggregates. Tumor-associated macrophages (TAMs) in C6-CD200S
tumors displayed dendritic cell (DC)-like morphology with multiple processes and CD86 expression. Furthermore,
CD3+, CD4+ or CD8+ cells were more frequently found in C6-CD200S tumors, and the expression of DC markers,
granzyme, and perforin was increased in C6-CD200S tumors. Isolated TAMs fromoriginal C6 tumorswere co-cultured
with C6-CD200S cells and showed increased expression of DCmarkers. These results suggest that CD200S activates
TAMs to become DC-like antigen presenting cells, leading to the activation of CD8+ cytotoxic T lymphocytes, which
induce apoptotic elimination of tumor cells. The findings on CD200S action may provide a novel therapeutic modality
for the treatment of carcinomas.
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CD200 is a transmembrane glycoprotein belonging to the
immunoglobulin superfamily, capable of exerting immunosuppressive
effects on cells expressing its receptor CD200R [1,2]. CD200 is
expressed in many tissues and cell types, such as lymphocytes, kidney
glomeruli, neurons and endothelial cells [3]. By contrast, CD200R is
expressed mainly by myeloid cells such as granulocytes, monocytes and
macrophages [2,4]. In the brain, neurons express CD200, which has
been implicated in the induction of immunologically inactive
phenotypes of microglial cells, a resident macrophage in the brain [5].
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tumor outgrowth or aggravates outcomes by suppressing anti-tumor
immune responses [4,6].Many kinds ofmalignant solid tumor cells [7–9]
as well as leukemia [10,11] express CD200, which is assumed to allow
tumor cells to evade immune surveillance mainly through suppression of
myeloid cell functions. However, there are conflicting hypotheses on the
roles of CD200 in some solid tumor progression. Talebian et al. [12]
reported that CD200 prevents melanoma cells from forming tumors or
metastasizing into the lung. A recent report using CD200 transgenic and
CD200R1 knock-out mice demonstrated that the enhancement of the
CD200-CD200R interaction in some cases led to inhibition ofmetastasis
and local growth of breast cancer [13].
Such contradictory data may be attributable to the presence of a splice
variant or truncated form of CD200 (CD200S) with a shorter amino
acid sequence [14,15], because the truncated form exerts an antagonistic
action on the immunosuppressive effects of CD200-CD200R interac-
tions [16]. The expression of a splice variant of CD200 devoid of exons
1 and 2, but containing exon 3-derived sequences has been reported
previously (see Figure 1A) [14–16]. A frame shift caused by the splicing
of exon 2 resulted in the appearance of a stop codon within the sequence
of exon 3, producing mRNA for CD200S. This alternative splicing of
CD200 is regulated by an exonic splicing enhancer and the splicing
regulatory protein SF2/ASF [17]. CD200S does not contain a C–C′
loop or complementarity determining region (CDR) 2,which is involved
in binding to CD200R; however, it does contain an F–G loop and
CDR3, which is also a binding domain for CD200R [18].Figure 1. Molecular structures of CD200L and CD200S (A), and c
expressing either CD200L or CD200S (B). (A) Expression of CD200L (A
amino acid sequence. CD200S contains F–G loop or CDR3 but not
CD200R. (B) Constructed vectors for transfection to original C6 gliomVarious normal murine tissues and organs have been shown to express
full-length CD200 (CD200L) and CD200S molecules [16]. In our
previous study, macrophages were found to accumulate densely in
ischemic rat brain lesions that expressed bothmolecules [15]. CD200has
been considered a candidate immune checkpoint allowing tumors to
evade anti-tumor immunity [19]. However, CD200L expression seems
to normally accompany the expression of CD200S. To determine the
specific roles of CD200 in tumor immunity, it is necessary to distinguish
the actions of CD200L and CD200S. Therefore, we established rat C6
glioma cell lines expressing either CD200L or CD200S and transplanted
them into the forebrains of newborn Wistar rats, which do not reject
transplanted cells owing to their immature immune system [20].
Consequently, CD200S expression in gliomas resulted in the prolonged
survival of the transplanted rats compared with rats bearing CD200L-
expressing tumors. Tumor-associated macrophages (TAMs) in the
CD200S-expressing tumors displayed dendritic cell (DC)-like pheno-
types. Our results suggest that CD200Smay have its own specific effects
on tumor immunity independently of CD200L.Materials and Methods
Cloning of full-length CD200S cDNA, construction of
retroviral expression vectors and establishment of C6 cells stably
expressing CD200L or CD200S
Expression plasmids encoding rat CD200L and CD200S were
constructed using the method described by Chen et al. [16]. cDNAonstructed vectors for establishment of C6 rat glioma cell lines
a) and CD200S (Ab). RNA splicing generates CD200S with a shorter
C–C′ loop or CDR2, all of which are responsible for the binding to
a cells to generate C6-L or C6-S cell lines.
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CD200 cDNA purchased from Origene (Rockville, MD) with the
following cloning primers containing BamHI and NotI respectively
(see Figure 1): CD200L; forward 5′-GGA TCC ATG GGC AGT
CCG GTA TTC AG-3′ and reverse 5′-ATG CGG CCG CTT ATT
TCA TTC TTT GCA TCC CCT G-3′, CD200S; forward 5′-ACG
GAT CCA TGA TCA CTT ACA GCA AAG CC-3′ and the same
reverse primer as for CD200L. The PCR products were inserted into
a BamHI–NotI site of pCX4-pur retrovirus vector (GenBank
accession No.: AB086386.1, gift from Dr. Tsuyoshi Akagi, KAN
Institute, Kobe, Japan). Virus particles were prepared in 293T cells by
co-transfecting pCX4-pur vector with pGP and pE-ampho retrovirus
packaging component vectors (Takara, Tokyo, Japan) using
lipofectamine 2000 as described elsewhere [21], and applied to C6
cells. Infected cells were selected by incubation with 1 μg/ml of
puromycin for 2 weeks. Expression of CD200 products was
confirmed by immunocytochemistry and quantitative real-time
RT-PCR (qPCR).
Human tissue analysis
Surgically resected human specimens of hepatocellular carcinoma
(HCC) and cholangiocellular carcinoma (CCC) were obtained with
informed consent and under approval by the local ethics committee
at Ehime University Hospital, Japan. Part of the tumors and
adjacent normal tissues were immediately frozen in liquid nitrogen
after surgery and stored at −80°C for subsequent extraction of
RNA. The frozen samples were homogenized in ISOGEN (Nippon
Gene, Tokyo, Japan) to prepare total RNA for RT-PCR as
described previously [22]. The total-RNA-derived cDNA was
amplified by PCR with primers (see Supplementary Table 1). PCR
conditions were as follows: 94°C for 1 min, followed by 30 cycles of
94°C for 30 s, 52°C (CD200) or 58°C (GAPDH) for 30 s, and
72°C for 1 min.
Experimental rat glioma model
Rat C6-glioma cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Wako, Osaka, Japan), containing 10% fetal bovine
serum (FBS; Wako), 4.5 g/L glucose, and a penicillin/streptomycin/
amphotericin B mixture (Wako). We prepared a 2.5 × 107 cells/ml
suspension of rat C6-glioma cells in phosphate-buffered saline (PBS) and
transplanted percutaneously 20 μl (5.0 × 105 cells/body) into the right
striatum of neonatal Wistar rats (within 24 h after birth) using syringes
with 29 G needles (Terumo, Tokyo, Japan) at 2 mm lateral from the
midline and 1 mm posterior from the bregma and 2 mm depth. A 1:1
mixture of C6-L and C6-S cells (5.0 × 105 cells in total/body) were
transplanted in the same way in some experiments. The health of the
transplanted rats was monitored every day and the survival periods were
plotted by Kaplan-Meier method. Statistical analyses were performed
with the use of a log-rank test.
Determination of the growth rates of the cell lines
To determine the growth rate of each cell line, the cells (3.0 ×
104cells/well) were seeded on 4-well culture plates in DMEM
containing 10% FS and 4.5 g/L glucose. One hour later, cells were
collected using 0.025% Trypsin-EDTA in PBS (Wako) to determine
the number of attached cells in a well. Cells in simultaneously prepared
cultures were counted on days 2, 3, and 5. The growth rate (% of the
data on day 1) was obtained by the formula; the growth rate (%) = (the
cell number in a well − the number of cells on day 1)/the number of cells
on day 1 × 100.Isolation of TAMs from the tumor masses
TAMs were isolated from rat brain tumors 3 weeks after
transplantation. Tumors were dissected out from rat brains and minced
with scissors. Minced tumors were incubated in 0.1% Trypsin-EDTA
(Sigma, St. Louis, MO, USA) while shaking for 15 min at room
temperature. After addition of DMEM containing 10% FCS, the
minced tumor suspensions were centrifuged at 1,000 rpm for 5 min at
4°C, and the pellets were recovered, resuspended in 4 ml DMEM
containing 3% FS, and filtered through a nylon mesh bag with 160 μm
pore. The filtrate was incubated in polystyrene dishes for suspension
culture (Sumitomo, Akita, Japan) for 30 min in a CO2 incubator.
TAMs but not the other cells preferentially attached to the dishes. The
dishes were rinsed three times with warm DMEM containing 3% (v/v)
FS to remove unattached cells. For qPCR and co-culture, purified
TAMs were scraped off with a rubber scraper.
Quantitative real-time RT-PCR (qPCR)
Total RNA isolated from tissue or cell homogenate was performed as
described [23]. cDNA was synthesized from RNA (0.5 μg) by reverse
transcription using ReverTra Ace qPCR RT Master Mix with gDNA
Remover (Toyobo, Osaka, Japan), according to the manufacturer's
instructions. For qPCR analysis, cDNAwas diluted at 1:3, and 1 μl was
used for triplicate qPCR on a MJ mini instrument (Bio-Rad, Hercules,
CA, USA) using Fast Start Universal SYBR Green (Roche Diagnostic
Japan, Tokyo, Japan). All gene-specific mRNA expression values were
normalized to GAPDH or Iba1 expression levels. Primer sequences are
listed in Supplementary Table 1.
TUNEL staining
Apoptotic cells in rat experimental tumors were detected by
TUNEL staining using a TACS 2 TdT-DAB In Situ Apoptosis
Detection Kit (Trevigen, Gaithersburg, MD, USA) according to the
manufacturer’s instructions [24]. Apoptotic cells in cryosections of rat
tumors 18 d after transplantation were stained brown by the use of
diaminobenzidine as a peroxidase substrate.
In vivo immunohistochemistry and morphometric analysis
Rats were sacrificed at 18 or 23 days after birth under deep
anesthesia. The brains were dissected and 2-mm-thick coronal slices,
which were immersed in 4% paraformaldehyde in PBS containing
2 mM MgCl2 for 2 h, and then immersed in 15% (w/v) sucrose in
PBS at 4°C for 2 days. The fixed slices were rapidly frozen at −80°C,
and cryosectioned into 10 μm-thick coronal sections. Immunohis-
tochemical observations were performed as previously described [23].
The cryosections were incubated overnight with the primary
antibodies shown in Supplementary Table 2. After washing with
Tris-buffered saline containing 0.02% Tween 20, sections were
treated with Cy3-conjugated anti-rabbit IgG secondary antibody or
Dylight488 labeled anti-mouse IgG secondary antibody (1:1,000;
Jackson Immunoresearch, West Grove, PA, USA). Hoechst 33342
(Sigma) was used for nuclear staining. The immunostained sections
were observed with a conventional microscope (BX-52, Olympus,
Tokyo, Japan), a Nikon A1 confocal laser scan microscope (CLSM;
Nikon, Tokyo, Japan) [25] or a scanning fluorescence microscope
(BZ-9000; Keyence, Osaka, Japan). Brain areas containing tumor
cells were morphometrically analyzed on Hoechst 33342-stained
sections, after the fluorescently stained area was binarized generating
black/white patterns using Adobe Photoshop CS5 Extended (Adobe
Systems, San Jose, CA, USA). The white area was measured using
ImageJ 1.43u as described elsewhere [26].
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Isolated TAMs (1.0×105 cells/well) from original C6 cells were
co-cultured for 48 h either with C6-e, C6-L or C6-S cells (3.0×104
cells/well) in 4-well plates. Some of the co-culture was fixed and
subjected to immunocytochemical staining according to the methods
described above. As secondary antibodies and phalloidin the following
agents were used; Cy3-conjugated anti-rabbit IgG secondary
antibody, DyLight 649-labeled anti rabbit secondary antibody
(Jackson Immunoresearch, West Grove, PA), and DY490-labeled
phalloidin (DYNOMICS, Germany). Total RNA was prepared from
other plates and the mRNA expression of DC markers was
investigated by real-time PCR.
Statistics
Statistical analyses were conducted using one-way analysis of
variance with Bonferroni's post-hoc test, or the log-rank test for
evaluating the survival rate. The co-culture data were analyzed with
the use of unpaired t-test. Pb0.05 was considered significant.
Results
Expression of mRNA encoding CD200L and CD200S in
human carcinoma tissues
Analysis of human carcinoma tissues revealed the expression of
mRNA encoding both CD200L and CD200S (Figure 2). HCC and
CCC tissues, as well as their surrounding normal tissues, were
subjected to RT-PCR analyses. All of the tissues analyzed, including
normal ones, expressed mRNA encoding both CD200L and
CD200S, as has been described in mice elsewhere [16].
Characterization of C6 rat glioma cell lines expressing
CD200L or CD200S
To investigate the roles of CD200L and CD200S differentially, we
established rat C6 glioma cells that specifically express either CD200L
or CD200S using retrovirus vectors containing their cDNA
(Figure 1B). Unaltered original rat C6 glioma cells did not express
CD200L or CD200S (data not shown). We first investigated whether
the established cell lines specifically expressed the transfected protein
by immunocytochemical staining using antibodies recognizing either
the N-terminal domain of CD200L (mouse monoclonal, clone OX2)
or the C-terminal domain (goat polyclonal), of which specificities
have been examined in our previous study (Figure 3, A–C) [15]. Our
immunostaining results show that neither the C-terminal nor the
N-terminal domain of CD200L was detected in C6 cells transfected
with the empty vector (C6-e cells; Figure 3A). Both of these domains
were detected in C6 cells transfected with the vector containing
CD200L-cDNA (C6-L cells; Figure 3B), while only the C-terminalFigure 2.Humanhepatocellular carcinoma (HCC)andcholangiocellular
carcinoma (CCC) as well as surrounding normal tissues expressed
mRNA encoding both CD200L and CD200S as revealed by RT-PCR.
T, tumor tissues; N, normal tissues.domain was detected in C6 cells transfected with the vector containing
CD200S-cDNA (C6-S cells; Figure 3C). The intracellular localization
of the C-terminal immunofluorescence was not the same in C6-L and
C6-S cells, thus post-translational modification of the CD200
molecules may have occurred as has been suggested previously [15].
Furthermore, we have confirmed the specific expression of the CD200
species by qPCR using two specific primer sets; ‘CD200 common
(com)’ primer sets amplified cDNA encoding both CD200L and
CD200S, ‘CD200L (L)’ primer sets amplified only cDNA for CD200L
(Figure 3D) [15]. C6-e cells did not express any of the mRNA. C6-L
cells expressed mRNA that could be amplified with both primer sets,
whereas C6-S cells expressed only mRNA that was amplified with
‘CD200 com’ primer sets. Thus, the three C6 cell lines, C6-e, C6-L,
and C6-S were successfully established to express no CD200, CD200L,
and CD200S, respectively.
Next, we compared the growth rate of the cell lines (Figure 3E)
and the expression of factors that potentially affect tumorigenicity
(Supplementary Figure 1). The established cell lines and the original
C6 cells showed no significant differences in their growth rate for 5 d
after seeding (Figure 3E). As revealed by qPCR analysis, there were
no significant changes in expression of mRNA encoding factors such
as chemokines, cytokines or an extracellular matrix protein, all of
which contribute to the growth of malignant tumors (Supplementary
Figure 1). mRNA level for proliferating cell nuclear antigen (PCNA)
was also not different among the four cell lines. Thus, from the qPCR
data it could not be predicted which cell line has the strongest
tumorigenic potential.
Tumorigenicity of CD200 cell lines and prolonged survival of
rats transplanted with C6-S cells
The four cell lines were transplanted into the right striatum
through the crania of neonatal rats within 24 h after birth. As shown
in Figure 4A, C6-e and C6-L cells formed apparent tumor masses in
the center of the forebrain 18 days after transplantation; however,
original C6 and C6-S cells did not form macroscopically apparent
tumor masses. Fluorescent nuclear staining with Hoechst 33342 to
identify the dense accumulation of cells revealed that tumors also
developed in the rat brains transplanted with original C6 and C6-S
cells (Figure 4B). To statistically analyze the growth of the brain
tumors, the brains were dissected out at 18 and 23 days after
transplantation and stained with Hoechst 33342 [26]. The ratio
obtained by dividing the nuclei-accumulated white area by total brain
area was used as an index for the tumor growth (Figure 4C). Tumor
areas were found to be smaller in the C6-S-transplanted brains than
those in brains transplanted with other cell lines.
The survival of rats transplanted with the four cell lines was
followed-up for 40 days after transplantation. Rats transplanted with
C6-S cells survived for a significantly longer period than rats transplanted
with the other lines of cells (Figure 4D). Rats transplanted with original
C6 cells survived longer than those transplanted with C6-e or C6-L cells
(Pb0.001). There was no significant difference in the survival period of
rats with C6-e andC6-L cells. Assuming that surviving rats at 40 days had
died on the next day, mean survival days were calculated (Figure 4E). Rats
transplanted with original C6 cells had a mean survival of 28.0 ± 6.7
(mean ± SD) days, compared with the mean survival with C6-e cells of
22.8 ± 5.9 days; C6-L cells of 22.1 ± 6.2 days; and C6-S cells of 33.6 ±
7.2 days. Thus, the rats bearing C6-S tumors survived for significantly
longer periods compared with rats bearing tumors formed from the other
cell types.
Figure 3. Characterization of established cell lines expressing CD200L and CD200S. (A–C) Immunocytochemical confirmation of CD200
expression with antibodies recognizing N- (OX2) or C-termini of CD200. The C6 cell line transfected with an empty vector (A, C6-e) did not
display positive immunostaining against either antibody. (B) The C6-L cell line was positive for both antibodies. (C) The C6-S line was only
reactive to the C-terminal antibody. (D) qPCR confirmed the specific expression of CD200L or CD200S. A primer set amplifying cDNA
derived from both CD200L- and CD200S-mRNAwas called common ‘Com’ (see Supplementary Table 1). The other primer set ‘L’ amplified
cDNA only derived from CD200L-mRNA. C6-e cells expressed none of the cDNA, C6-L cells expressed both, and C6-S cells expressed
cDNA amplified only by the Com primer set. (E) Growth curves of each cell line. Data from four independent cultures are expressed as
means ± SD except for the data of Empty at 5 days, which is expressed as mean − SD.
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We postulated that the smaller size of the C6-S tumors likely led to
the prolonged survival of the rats, thus, we suspected an enhanced rate
of cell death of the C6-S tumor cells. Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining showed an
increased number of apoptotic cells in the C6-S tumors than in the
C6-L tumors (Figure 5A). Expression of cleaved caspase-3 (CC3),
another marker of apoptosis [27], was also frequently found in C6-S
tumors (Figure 5B). CD11b+ TAMs with multiple processes did not
display CC3-immunoreactivity. The density of CC3+ cells was
compared among the three tumor types (Figure 5, C–E), with denser
accumulation of CC3+ cells found in the C6-S tumors. Dense tumor
cell accumulation in C6-e (Figure 5Cd) and C6-L (Figure 5Dd)
tumors was revealed by Hoechst 33342 staining, whereas C6-S
tumors formed only small aggregates (Figure 5Ed). Closer observation
revealed that only a few CC3+ cells were present in the regions with
dense Hoechst 33342-staining in the C6-e (Figure 5Fa) and C6-L
(Figure 5Fb) tumors. By contrast, many CC3+ cells were found in thetumor cell aggregates in the C6-S tumors (arrowheads in Figure 5Fc).
The results suggest that apoptotic cell death occurred more frequently
in the C6-S tumors and may be a likely cause for the smaller tumor
sizes and prolonged survival of the rats.
Dendritic cell morphology of TAMs in the C6-S tumor
TAMs in each tumor mass were stained with an antibody directed
against Iba1, a monocyte/macrophage/microglia marker [28]
(Figure 6A). Although all tumor types contained densely accumulated
TAMs, TAMs in the C6-S tumors showed a distinct morphology
characterized by multiple short processes, which resemble DCs
(Figure 6Ac; also see Figure 9C). Furthermore, CD4+ cells were more
frequently found in the C6-S tumors than in the C6-L tumors
(Figure 6B). Many CD3+ lymphocytes were found in the C6-S tumors,
some of which were CD4+ suggesting they were helper T cells (yellow
arrowheads) (Figure 6C). CD3+/CD4- cells were likely CD8+ T cells
(pink arrowheads). Indeed, CD8+ cells were often found in the C6-S
tumors but not in the C6-L tumors (Figure 6D). Figure 6E shows the
Figure 4. Tumor growth and survival of rats transplanted with the four lines of cells. (A) Macroscopic overviews of rat brains bearing
tumors of the four cell lines. The brains were dissected and sliced on 18 days after transplantation. Apparent tumor masses (asterisks)
were observed in the brains transplanted only with C6-e and C6-L lines. (B) Cryosections of the fixed brain were fluorescently stained with
Hoechst 33342 to identify the spread of tumor cells. C6-e (Bb) and C6-L (Bc) cells formed large tumor masses. Original C6 cells (ori-C6)
formed an apparent but smaller tumor mass (Ba, arrowheads). There was no apparent tumor mass in the brain transplanted with C6-S
cells (Bd). (C) Ratios of tumor area/total brain area were obtained by measuring the area clearly stained with Hoechst 33342, where tumor
cells densely accumulated. The brains were dissected on 18 and 23 days after transplantation. Tumor areas were smaller in the
C6-S-transplanted brains. Data (n=4 at each time point) are expressed as means ± SD. (D) Kaplan-Meier survival plots of rats transplanted
with each C6 cell line by 40 days after transplantation. As revealed by log-rank test, rats transplanted with C6-S cells were survived
significantly longer (Pb0.001) than rats bearing tumors from other cell lines. (E) Mean survival days were calculated, by assuming that all
surviving rats die at 41 days after transplantation. C6-S-transplanted rats survived longer by 5.5 days versus rats bearing original C6 tumors
and 11 days versus C6-e and C6-L tumors. *P b .01, **P b .001.
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with processes; a probable evidence for cross-presentation by the TAMs
in the C6-S tumors. Expression of the co-stimulatory factor CD86 was
expressed bymost TAMs in the C6-S tumors (Figure 6F). CD86may be
expressed by other cells than TAMs, taken its rather high expression in
C6-ori, -e or L tumors (Supplementary Figure 2).
Characterization of the four types of tumors and their derived
TAMs by qPCR
We dissected each tumor type to subject the tissues to qPCR analyses
21 days after transplantation (Figure 7A). ‘CD200 com’ primers
amplified both CD200L and CD200S cDNA and detected a high
level of expression of CD200 in the C6-L and C6-S tumors. ‘CD200L’
primers detected high expression of CD200L only in the C6-L tumors.
However, low levels of CD200LmRNAwere found in the other tumors,
an indicative of expression of CD200 by other types of cells such as
endothelial cells [15]. There are two CD200R isoforms; R1 and R2
[4,15,29].No significant differences were found in the expression levels ofmRNA encoding CD200Rs in each tumor type, suggesting that the
density of CD200R+ TAMs was not significantly different in each tumor
type (Supplementary Figure 2). This may correlate with the expression of
Iba1-mRNA that was also at similar levels among the four types of
tumors. mRNA encoding MHC class II α, CD11c, and CD80, all of
which are DC markers, showed significantly higher expression in the
C6-S tumor than in other types of tumors. F4/80 and CD68, known of
their expression byDCs [30,31], was highly expressed in the C6-S tumor.
Expression of CD4-mRNA showed a tendency to be elevated in the C6-S
tumors, but the change was not significant. mRNA encoding CD3δ, ε,
andγ as well as CD8α and βwas highly expressed in theC6-S tumors, an
indicative of more accumulation of T cells in the C6-S tumor than in the
other tumors. Furthermore, the levels of mRNA encoding granzyme and
perforin were elevated in the C6-S tumors. Interferon-γ (IFNγ) mRNA
showed a tendency to be elevated in the C6-S tumors. NK cells express
IFNγ as well as granzyme and perforin [32,33], leading to apoptosis of
tumor cells. The observation thatCD56 expressionwas notmarked in the
C6-S tumor suggests that NK cells were not responsible for the apoptotic
Figure 5. Apoptotic cell death in the tumor region of rat brains. (A) TUNEL staining detected more apoptotic cells in the brain tumor
composed of C6-S cells (Ab) than in the tumor composed of C6-L cells (Aa). (B) Apoptotic cells identified by immunostaining with antibody
to cleaved caspase 3 (CC3) in the C6-S tumor. CD11b+ TAMs in tumors. Ba shows a 2D image and Bb a 3D image. Note the morphology
of CD11b+ TAMs displaying polygonal shape with multiple processes. (C–E) Double immunohistochemical observation of the tumors
consisting of C6-e (C), C6-L (D), or C6-S (E) cells detecting CD11b and CC3. Densely accumulated tumor cells were present in the tumors
of the C6-e and C6-L cells as revealed by Hoechst 33342 staining, whereas the tumor cells in the C6-S tumor formed only small
aggregates (Ed). The C6-S tumor contained a number of CC3+ apoptotic cells that were scattered throughout the tumor region.
(F) Enlarged micrographs of those shown in (C–E). Although many CC3+ apoptotic cells were found in C6-e (Fa) and C6-L (Fb)-tumors,
most of those were found in non-tumor regions where were observed as less densely distributed Hoechst 33342+ nuclei. By contrast,
apoptotic cells accumulated in the tumor region (arrowheads) in the C6-S tumor (Fc).
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another possible source of granzyme and perforin [33], the involvement of
NKT cells was unlikely because of the high expression of CD16 mRNA
in the C6-S tumor. C-type lectin domain family 9A (CLEC9A) was
highly expressed in the C6-S tumor, which is expressed by myeloid DCs
and involved in cross-presentation [34].
In this series of experiments, we investigated whether CD200S
induces a M1-like phenotype in TAMs, which may originally have
M2-like properties, which support tumor growth [35]. Therefore,
we investigated the expression of M1 and M2 markers such asarginase-1 (Arg-1), CD163, inducible nitric oxide synthase (iNOS),
interleukin-10 (IL-10), IL-12 [15,36,37], tumor necrosis factor α
(TNFα), transforming growth factor (TGF) β1 as shown in
Supplementary Figure 2. However, there were no significant
changes in expression in these factors among the tumor types.
Factors affecting apoptotic tumor cell death such as Bcl-xL, Bax, Fas,
or FasL expression were not significantly different among the tumors
in their mRNA levels (Supplementary Figure 2). Among these, FasL
expression appeared to be elevated in C6-S, but it was not a
significant change.
Figure 6. DC-likemorphology of TAMs and accumulation of CD4+ or CD8+ cells in the C6-S tumor. (A) Inclined 3D images on Iba1+ TAMs in
the C6-ori (Aa), C6-e (Ab), C6-L (Ac), and C6-S (Ad) tumors. Compared with TAMs in other types of tumors, those in the C6-S tumor displayed
DC-like ramified morphology characterized by multiple processes or spikes. (B) CD4+ cells and structures were more abundant in the C6-S
tumor (Bb) than the C6-L tumor (Ba). (C) There were abundant CD4+ (Ca) and CD3+ (Cb) T cells in the C6-S tumor. Yellow arrowheads denote
CD3+/CD4+ cells, pink ones CD3+/CD4- cells. Iba1+ TAMswith processes surrounded CD4+ lymphocyte-like round cells, as revealed by 3D
images. (D) CD8+ cells and structures were frequently present in the CD200S-tumors (Db), whereas they were not in the C6-L tumor (Da).
(E) CD8+ cells with round morphology were often intimately associated with process-bearing TAMs. (F) Most TAMs in the C6-S tumor were
CD86+, since they displayed yellow or orange colors due to the mergence of Iba1 (red) and CD86 (green) immunofluorescence.
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cells (data not shown). Their expression in the tumors was
investigated (Figure 7 and Supplementary Figure 2). CCL12,
CXCL10 and CXCL16 mRNA were highly expressed in the C6-S
tumor. CCL12 may play a role in recruitment of lymphocytes and
monocytes [38]. CXCL10 is expressed by a variety of cells and a
chemoattractant for monocytes, T cells and NK cells [39]. CXCL16
may be expressed by the DC-like TAMs in the C6-S tumor, while
recruiting activated T cells based on notions described elsewhere [40].
These three chemokines may play a role in recruitment of T cells. On
the other hand, there were no significant differences in expression
levels of mRNA encoding CCL6, CCL7, CCL9, CXCL1, or CXCL2.
Shortly after isolation from each type of tumor, TAMs were
subjected to qPCR analyses (Figure 7B). The isolated TAMs from the
C6-S tumors expressed mRNA encoding major histocompatibility
complex (MHC) class II α and CD11c at higher levels than those
from other types of tumors. The TAMs from the C6-S tumors also
showed a tendency to have elevated CD86 mRNA expression.Expression of DC markers in co-culture with TAMs and C6-S cells
TAMs isolated from original C6 tumors were co-cultured with C6-L
or C6-S cells for 48 h, followed by collection of total RNA for
immunocytochemical staining and qPCR analyses. There were no
CD80+ TAMs found in co-culturewith C6-L cells (Figure 8A), whereas
some of the CD11b+ TAMs were CD80+ following co-culture with
C6-S cells (Figure 8B). Note that C6 cells did not show a damaged
morphology, indicating that TAMs did not have cytotoxic activity
against co-cultured tumor cells. MHC class II α, CD11c and CD80
mRNA expression was significantly elevated following co-culture with
C6-S cells compared with C6-L cells (Figure 8C).
A mixed cell tumor
To further investigate the tumor-suppressive effects of CD200S in
vivo, a 1:1 mixture of C6-L and C6-S cells were transplanted into the
brain of neonatal rats. CD200L and CD200S mRNA expression in
the mixed tumor dissected 21 days after transplantation was evaluated
by qPCR using the two primer sets; CD200L and CD200 common
Figure 7. Expression levels in tumors and isolated TAMs of mRNA encoding molecules related to CD200, DCs, lymphocytes and T cells,
as revealed by qPCR. Data are shown in an alphabetical order. (A) cDNA was prepared from tumor masses dissected out 21 days after
transplantation. CD200-mRNA amplified with ‘CD200 com’ primers was highly expressed by C6-L and C6-S tumors, whereas the
CD200L-mRNA level was high only in the C6-L-tumors. The C6-S-tumors expressed DC markers, MHC class II α, CD11c, and CD80 at
significantly higher levels than other tumors. Expression of mRNA encoding lymphocyte markers CD8α and β, CTL-related
apoptosis-inducing molecules, granzyme, and perforin was significantly higher in the C6-S tumors. Despite not showing statistical
significance, CD4 and IFNγ-mRNA were also highly expressed in the C6-S tumors. CLEC9A, which is expressed by myeloid DCs and
responsible for cross-presentation, and chemokines (CCL12, CXCL10 and CXCL16), which are invovlved in recruitment of monocytes and
lymphocytes, are also highly expressed in the C6-S tumor. (B) Shortly after isolation from the tumor mass, TAMs were subjected to qPCR
analysis. TAMs from the C6-S-tumors expressed MHC class II α-, and CD11c-mRNA was expressed at significantly higher levels than in
TAMs from other tumors. CD86-mRNA expression in TAMs from the C6-S tumors was also high. Data from 3 tumors of each cell lines are
expressed as means ± SEM. *P b .05, **P b .01, ***P b .001 versus CD200S; #P b .05, ##P b .01 versus CD200L.
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Figure 8. DC markers on TAMs were induced by co-culturing with C6-CD200S. TAMs isolated from original C6 brain tumors were
cocultured with C6-L- and C6-S-cells. (A and B) The cells were fixed and immunostained with antibodies to CD11b and CD80. FITC-labeled
phalloidin was used to identify cocultured C6 cells by staining actin filaments. The white cells in Aa or Bb are TAMs and green cells are C6
cells. (A) TAMs were cocultured with C6-CD200L cells. (B) TAMs were cocultured with C6-CD200S cells. There were some CD80+/Iba1+
TAMs only in the coculture with C6-CD200S cells (Bc). (C) qPCR experiments showed that coculture with TAMs and C6-S cells
significantly enhanced expression of mRNA encoding MHC class II α, CD11c, and CD80. The data (n = 5) were normalized by dividing the
% GAPDH data obtained with C6-L or C6-S cells by the data with C6-e cells and are expressed as means ± SEM. *P b .05.
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common were 674 ± 169 % and 411 ± 80.8 %, respectively (data from
3 rats are expressed as % of GAPDH mRNA and as means ± SEM).
Thus, the two CD200 molecular species were actually expressed in theFigure 9. Apoptotic cell death and the morphology of TAMs in the
(A) Most tumor cells of the mixed cell tumor underwent apoptotic ch
mixed tumor (C6-S+L) displayed ramified morphology characterized
observed in the same way as those show in (B). The TAMS displayed D
rather smooth cell surfaces devoid of ramified processes that weremixed tumor. The brain sections were subjected to immunohisto-
chemical staining with antibodies to CC3 and Iba1. As shown in
Figure 9, CC3+ apoptotic cells were abundantly present in the tumor
regions that were identified with densely accumulated nucleitumor prepared by transplanting mixture of C6-S and C6-L cells.
anges as revealed by CC3-immunostaining. (B) Iba1+ TAMs in the
with multiple processes. (C) Iba1+ TAMs in the C6-S tumor were
C-like ramified morphology. (D) Iba1+ TAMs in C6-L tumor showed
distinct from those of Tams in the C6-S and the C6-S+L tumors.
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C6-S alone tumor. Furthermore, DC-like ramified morphology of
TAMs in the mixed tumor was not distinguishable from that in the
C6-S tumor (Figure 9C). TAMs in C6-L tumor displayed amoeboid
shape (Figure 9D).
Discussion
The present study revealed that C6-S cells formed intracranial tumors in
rats, the sizes of which were smaller than those consisting of C6-L or
control cells. Furthermore, rats bearing C6-S tumors survived for longer
than those with other tumors. The smaller size of C6-S tumorsmay have
been caused by enhanced apoptotic cell death as revealed by TUNEL
staining and immunohistochemistry for CC3. C6-S tumor cells induced
a DC-like phenotype with multiple short processes in TAMs.
Morphological observations demonstrated the presence of CD3+ T
cells and the intimate attachment of DC-like TAMs to CD4+ or CD8+
cells, suggesting antigen presentation by TAMs to T cells. qPCR studies
showed significantly elevated expression of DCmarkers, T cell markers,
perforin and granzyme in C6-S tumors. When co-cultured with C6-S
cells, TAMs from the original C6 tumors expressed DC markers.
Collectively, these results suggest the following processes to induce
apoptotic elimination of tumor cells: C6-S cells induceTAMs to acquire
a DC-like nature leading to the presentation of tumor cell antigens to
T cells. In turn, antigen presentation primes CD4+ T cells to stimulate
CD8+ CTLs to eliminate tumor cells by releasing perforin and
granzyme. Direct activation of CTLs in C6-S tumors through
cross-presentation by DC-like TAMs may primarily occur [41], as
expression of mRNA encoding CD4 and IFNγ was not markedly
increased in C6-S tumors, whereas mRNA expression for CD8,
granzyme, and perforin was much more evident compared with
expression levels in the tumors formed by other cell lines. High-level
expression of CLEC9AmRNA in C6-S tumor may also be a suggestive
of cross-presentation [34]. CD3 and CD16 mRNA was also highly
expressed only in the C6-S tumor, indicating that the source of
granzyme and perforin is CTLs rather than NKT or NK cells.
To date, CD200 has been considered as an immunosuppressive
molecule that partly resembles the well-studied immune checkpoints,
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programed
cell death protein 1 (PD-1) [42,43]. Humanizedmonoclonal antibodies
ipilimumab and nivolumab, which target CTLA-4 and PD-1,
respectively, have been clinically introduced and proven to be effective
for several kinds of cancers. Similarly, inhibitory agents for the
CD200-CD200R interactions have been investigated [44,45].
CD200-derived short peptides [44] or an anti-CD200 antibody
[46,47] have been shown to prolong survival of tumor bearing animals
or to suppress tumor growth. However, the effects of the
CD200-CD200R interaction on tumor immunity have been contro-
versial [12,13,19]. Some studies have shown that CD200 inhibits tumor
growth andmetastases inmelanoma [12] and breast cancer [13]models.
Such a tumor-suppressing effect of CD200 has been attributed to its
suppressive effects on myeloid cells, which can potentially cause
pro-tumorigenic inflammation [19]. These ideas may suggest that
inhibitors of the CD200-CD200R interaction have less significant
anti-tumor effects than the immune checkpoint inhibitors against
CTLA-4 or PD-1. In this study, we could not find any effects of C6-L
cell lines that were distinct from those of C6-e tumors in terms of tumor
growth or on the survival periods of tumor-bearing rats. This
observation suggests that CD200L does not have marked effects on
tumor immunity at least in the present rat glioma model.CD200+macrophages have been identified in the ischemic core region
of a rat stroke model [15,48]. These are not activated microglia but bone
marrow-derived cells [49]. CD200+ macrophages in an ischemic brain
lesion expressed both CD200L and CD200S in addition to CD200R
[15]. Since the cells were densely accumulated with intimate attachment
to each other, it is likely that both CD200L and CD200S can affect their
own functions through binding to CD200R. The CD200L+/CD200S+
macrophages displayedM1-like phenotypes with expression of IL-1β and
iNOS, suggesting that immune activating effects of CD200S precede
immunosuppression by CD200L. As shown in the present study
(Figure 2) and the previous study [16], CD200L appears to be
simultaneously expressed with CD200S. Thus, the actions of a
suppressor CD200L and an activator CD200S may compete in the
regulation of tumor immunity. Although the outcome of the competition
might be altered by the context of the tumor pathophysiological processes
as suggested by others [13], CD200S, at least in some cases, may play a
more critical role in tumor immunity than CD200L. The different
actions of CD200L and CD200S might be attributable to the different
binding affinity to the CD200R isoforms; there are two known isoforms
in humans and four in mice [4,29]. In rats, CD200R1 and R2 isoforms
may be expressed as shown in Supplementary Figure 2. It remains to
be elucidated whether CD200L and CD200S have different affinities
to CD200R1 or R2 causing the distinct actions on tumor growth
or apoptosis.
The present study proposes the novel possibility that molecules
mimicking CD200S functions may be used as an anti-tumor
intervention. CD200S can alter the nature of TAMs to display a DC-like
phenotype causing activation of CD4+ or CD8+ T lymphocytes, leading
to apoptotic glioma cell death. Despite that CD200S is thought to have
antagonistic effects on CD200L-CD200R interactions [16], the present
data suggest that CD200S directly affects CD200R+ TAMs. Normally,
only negligible numbers of CD200L+ cells are found in recipient rats
compared with the huge number of CD200L-/CD200S+ tumor cells.
Some peptides mapping to the presumptive CDR3 or F–G loop of
CD200 are reported to overcome immunosuppressive effects of
CD200Fc or soluble CD200L peptide in the induction of CTLs and
the release of TNFα in mixed lymphocyte cultures [45]. Interestingly,
CD200S contained these peptide sequences. By contrast, peptides
mapping to the CDR2 region of CD200 are reported to exhibit a similar
effect to that of CD200Fc. CD200S does not have the CDR2 region.
Furthermore, some CDR3-derived peptides consisting of a
CD200R-binding domain showed curative effects in a murine breast
cancermodel [44].Our present experiment using the co-culture of TAMs
from an original C6 tumor with C6-L or C6-S cells showed the direct
effect of CD200S on CD200R+ TAMs. Collectively, these data suggest
that CD200S not only antagonizes the CD200-CD200R interaction but
also directly exhibits activating effects on CD200R+ myeloid cells
includingTAMs. Furthermore, it has been speculated that CDR3or F–G
loop-derived peptides with antagonistic effects on the CD200-CD200R
interaction act directly on DCs, increasing both the number of CD8+
CTLs and the release of TNFα [44,45]. However, the peptides have not
been shown to upregulate expression of DC markers by TAMs.
Therefore, the action of the peptides with the partial sequence ofCD200S
may not be completely the same as that of CD200S. If some sequences in
CD200S critical for the action of inducing DC-like phenotypes are
determined, a peptide containing the relevant sequences might be a novel
intervention to treat carcinomas.
When a mixture of C6-L and C6-S cells were transplanted into the
neonatal rat brains, the formed tumor displayed indistinguishable
240 Prolonged Survival in a Rat Glioma Model by Tumor-Associated Macrophages Kobayashi et al. Neoplasia Vol. 18, No. 4, 2016histological features from those of C6-S tumor, in terms of the
presence of DC-like TAMs and abundant apoptotic cells. This
observation suggests that the effect of CD200S overcame that of
CD200L on the immune system. Specific actions of solely expressed
CD200S on tumor immunity have not been reported, although
malignant tumors express both CD200 species as shown in Figure 2.
It is necessary to determine whether the solely expressed CD200S in a
single cell devoid of CD200L is critical for induction of DC-like cells
in the tumor. Nevertheless, the finding in the mixed tumor would be
a hint to develop a novel curative intervention using CD200S itself or
its related molecules.
In conclusion, we first demonstrated that CD200S with only one of
the two domains of CD200L that binds to CD200R exhibit unique
actions on TAMs inducing them to differentiate into DC-like cells. The
TAMs activate CTLs to induce apoptotic tumor cell death. The
anti-tumor action of CD200S appeared to bemore active than that of the
CD200-derived peptides that antagonize CD200-CD200R interactions,
because CD200S exhibits its actions on TAMs virtually in the absence of
CD200L. The results shown heremay provide a novel strategy to develop
a therapy for malignancies that evade anti-tumor immunity.
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